Kamada Ltd. (KMDA)
- Insider Monkey
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript March 6, 2024 Kamada Ltd. beats earnings expectations. Reported EPS is $0.09, expectations were $0.05. KMDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Kamada Ltd.’s Fourth Quarter and […]
- GlobeNewswire
Kamada Issues 2024 CEO Letter to Shareholders
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2023 was another successful period in our com
- GlobeNewswire
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35% Year-over-YearStrong Momentum Supports Expected Double-Digit Growth with Anticipated Fiscal Year 2024 Revenues in Range of $156 to $160 Million and Expected Adjusted EBITDA in Range of $27 to $30 MillionKamada Maintains Financial Strength to Accelerate Growth and Pursue Compelling New Business Developm
